PROCEPT BioRobotics PRCT
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
PROCEPT BioRobotics (PRCT) Core Market Data and Business Metrics
Latest Closing Price
$57.74Price-Earnings Ratio
-28.03Total Outstanding Shares
54.82 Million SharesDividend
No dividendSIC Description
Surgical & Medical Instruments & ApparatusPrimary Exchange
NASDAQHeadquarters
150 Baytech Drive, San Jose, CA, 95134
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 1,015,087 Shares | 5.74 | 3/14/2025 | 5,829,532 Shares |
| 1,234,439 Shares | 4.11 | 2/28/2025 | 5,079,251 Shares |
| 686,795 Shares | 8.28 | 2/14/2025 | 5,684,573 Shares |
| 1,137,185 Shares | 5.26 | 1/31/2025 | 5,980,863 Shares |
| 640,612 Shares | 11.04 | 1/15/2025 | 7,073,409 Shares |
| 549,775 Shares | 12.52 | 12/31/2024 | 6,885,494 Shares |
Cash Flow Statement
July 1, 2023 to June 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities | $-17.48 Million |
| Net Cash Flow From Financing Activities, Continuing | $172.87 Million |
| Net Cash Flow | $63.63 Million |
| Net Cash Flow From Operating Activities | $-91.76 Million |
| Net Cash Flow From Financing Activities | $172.87 Million |
| Net Cash Flow From Operating Activities, Continuing | $-91.76 Million |
Income Statement
July 1, 2023 to June 30, 2024
| Metric | Value |
|---|---|
| Net Income/Loss Attributable To Parent | $-103.71 Million |
| Cost Of Revenue | $79.93 Million |
| Costs And Expenses | $286.22 Million |
| Preferred Stock Dividends And Other Adjustments | $0 |
| Basic Earnings Per Share | $-2.06 |
| Operating Expenses | $206.29 Million |
Comprehensive Income
July 1, 2023 to June 30, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss | $-77.78 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss Attributable To Parent | $-103.70 Million |
| Comprehensive Income/Loss | $-103.73 Million |
Balance Sheet
July 1, 2023 to June 30, 2024
| Metric | Value |
|---|---|
| Noncurrent Liabilities | $79.73 Million |
| Other Non-current Liabilities | $28.32 Million |
| Equity Attributable To Noncontrolling Interest | $0 |
| Other Current Assets | $278.03 Million |
| Current Liabilities | $42.84 Million |
| Inventory | $43.87 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||